SelectQuote Inc. Signals Cash-Flow Upside Amid Headwinds

SelectQuote Inc ((SLQT)) has held its Q3 earnings call. Read on for the main highlights of the call.

SelectQuote Inc.’s latest earnings call struck a cautiously upbeat tone, as management pointed to steady revenue growth, expanding margins, and improving cash generation prospects while acknowledging policy headwinds and an accounting boost that flattered results. Executives leaned heavily on the strength of the Senior segment and SelectRx momentum to argue that long-term cash flows are underappreciated by the market.

Consolidated Revenue Growth

SelectQuote posted consolidated revenue of $431 million for the quarter, a 6% increase from a year earlier that showed resilience across business lines. Management framed the performance as validation of its diversified model, noting that growth came despite regulatory and reimbursement pressures in parts of the healthcare portfolio.

Adjusted EBITDA Expansion

Adjusted EBITDA climbed 18% year over year to $45 million, underscoring improved profitability and operating leverage. Executives did note that roughly $14 million of that reflected a favorable commissions receivable adjustment, and that excluding it, consolidated EBITDA margin would have been close to 7%.

Senior Segment Strength

The Senior segment remained the earnings engine, with revenue rising 8% to $183 million on 4% growth in approved Medicare Advantage policies. Senior adjusted EBITDA reached $59 million, and even without the $14 million accounting benefit, the segment delivered a 26% margin, extending a four-year streak of at least 25% profitability during peak enrollment seasons.

Commissions Receivable and Backbook Visibility

Management highlighted nearly $1 billion in Medicare Advantage commissions receivable as evidence of a sizable backbook of future cash flows. The $14 million favorable change in estimate was tied to improved renewal expectations, with recapture rates cited around 34%, reinforcing the company’s confidence in the durability of its commission stream.

SelectRx Member and Operational Momentum

Healthcare Services, led by SelectRx, generated $199 million of revenue with membership of about 117,000, up 11% year over year. Prescriptions shipped have surged 64% versus two years ago, and SelectRx posted $5 million of adjusted EBITDA, marking a sequential improvement that management views as a key inflection.

Path to Meaningful SelectRx Profitability

Executives reiterated that SelectRx is on track to achieve a $40 million to $50 million EBITDA run-rate in the near term, driven by scale and efficiency gains. They argued that as this pharmacy platform matures, it can become a material profit contributor and a more visible value anchor alongside the Senior insurance business.

Facility Efficiency and Scalability

A centerpiece of that story is the Olathe, Kansas distribution facility, which currently handles less than 20% of prescriptions but is already delivering over 30% efficiency gains versus older sites. With significant unused capacity, management sees ample room to ramp volume through Olathe, lowering per-script costs and expanding margins over time.

Marketing and Productivity Improvements

The company also pointed to better unit economics across its agent and marketing engine, noting that policies per agent are up 1% compared with two years ago. Over the same period, marketing spend per approved policy fell 14%, producing a consolidated revenue-to-CAC multiple of 6.7x and signaling more disciplined customer acquisition.

Life Insurance Steady Contribution

Life insurance remains a modest but steady contributor, with revenue up 4% to $48 million and adjusted EBITDA of $6 million in the quarter. Final Expense commissions grew more than 8% year over year and continue to offset pressure in other life products, giving the segment a stable growth base.

Inflation Reduction Act Impact on Revenue

Not all trends were tailwinds, as SelectRx felt the impact of the Inflation Reduction Act, which put maximum fair prices on certain high-cost drugs starting in January. The company said this change weighed on sequential top-line revenue, though it received $13 million in manufacturer refunds and estimated the EBITDA impact in the low single-digit millions.

PBM Reimbursement and Earlier Headwinds

Earlier in the year, SelectRx faced carrier-specific PBM reimbursement changes that pressured revenue and margins, highlighting the fragility of pharmacy economics. Management now believes those reimbursement rates have normalized under a new multi-year agreement, suggesting a more predictable backdrop going forward.

One-Time Accounting Adjustment Aiding Results

Management acknowledged that the quarter’s profitability benefited from the one-time $14 million favorable commissions receivable adjustment, which boosted both reported EBITDA and margins. While executives defended the underlying assumptions, investors were reminded that this benefit will not repeat and should be stripped out when assessing sustainable earnings power.

Potential Timing Risk in Senior Approval Rates

The call also flagged a timing-related risk as Medicare Advantage approval rates were materially higher during this year’s Open Enrollment, supporting the quarter’s strength. Executives cautioned that some of this may reflect a pull-forward of approvals that would otherwise land in the fourth quarter, which could make near-term policy counts and revenue recognition more volatile.

Term Life Competitiveness

Within the Life segment, Term Life sales remained under pressure as competitive dynamics and shifting consumer media habits weighed on volume. Strength in Final Expense and steady profitability helped limit the overall impact, but management suggested that Term Life will likely remain a tougher battleground.

Market Valuation Disconnect

Throughout the call, leadership underscored what they see as a sharp valuation disconnect, contrasting a sub-$200 million market cap with nearly $1 billion of commissions receivable on the balance sheet. They hinted that this gap is driving strategic urgency and exploration of options that could help crystalize the value of the company’s long-duration cash flows.

Forward-Looking Guidance and Outlook

Guidance remained intact, with management reaffirming fiscal 2026 revenue expectations of $1.61 billion to $1.71 billion and adjusted EBITDA of $90 million to $100 million. Executives said they expect to exit FY26 on strong footing, deliver meaningful operating cash-flow improvement next year, compound cash-flow growth into FY27, and delever over time as SelectRx scales and Senior continues to generate high-margin earnings.

SelectQuote’s earnings call presented a story of solid underlying momentum, with growing revenue, expanding margins, and a sizable backbook that management believes the market is overlooking. While regulatory changes, PBM dynamics, and one-time accounting benefits complicate the near-term picture, the company is signaling confidence that its operational improvements will translate into stronger and more visible cash generation over the next two years.